Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients

被引:6
作者
Hatairaktham, Suneerat [1 ]
Masaratana, Patarabutr [1 ]
Hantaweepant, Chattree [2 ]
Srisawat, Chatchawan [1 ]
Sirivatanauksorn, Vorapan [1 ]
Siritanaratkul, Noppadol [2 ]
Panichkul, Narumol [1 ]
Kalpravidh, Ruchaneekorn W. [1 ]
机构
[1] Mahidol Univ, Fac Med, Dept Biochem, Siriraj Hosp, 2 Wanglang Rd, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Div Hematol, Dept Med,Siriraj Hosp, Bangkok, Thailand
关键词
Curcumin; Curcuminoids; Inflammation; Iron overload; Oxidative stress; Thalassemia; TRANSFERRIN-BOUND IRON; PEPTIDE HEPCIDIN; MAJOR PATIENTS; DEFERIPRONE; CYTOKINES; BENEFITS; REMOVAL; GENE;
D O I
10.1007/s00277-020-04379-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory activities. Effects of curcuminoids in thalassemia patients have been explored in a limited number of studies using different doses of curcuminoids. The present study aims to evaluate the effects of 24-week curcuminoids supplementation at the dosage of 500 and 1000 mg/day on iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfused beta-thalassemia/Hb E patients. In general, both curcuminoids dosages significantly lowered the levels of oxidative stress, hypercoagulability, and inflammatory markers in the patients. In contrast, reductions in iron parameter levels were more remarkable in the 1000 mg/day group. Subgroup analysis revealed that a marker of hypercoagulability was significantly decreased only in patients with baseline ferritin <= 1000 ng/ml independently of curcuminoids dosage. Moreover, the alleviation of iron loading parameters was more remarkable in patients with baseline ferritin > 1000 ng/ml who receive 1000 mg/day curcuminoids. On the other hand, the responses of oxidative stress markers were higher with 500 mg/day curcuminoids regardless of baseline ferritin levels. Our study suggests that baseline ferritin levels should be considered in the supplementation of curcuminoids and the appropriate curcuminoids dosage might differ according to the required therapeutic effect. Thai Clinical Trials Registry (TCTR): TCTR20200731003; July 31, 2020 "retrospectively registered"
引用
收藏
页码:891 / 901
页数:11
相关论文
共 50 条
  • [21] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Taher, Ali T.
    Porter, John B.
    Viprakasit, Vip
    Kattamis, Antonis
    Chuncharunee, Suporn
    Sutcharitchan, Pranee
    Siritanaratkul, Noppadol
    Galanello, Renzo
    Karakas, Zeynep
    Lawniczek, Tomasz
    Habr, Dany
    Ros, Jacqueline
    Zhu, Zewen
    Cappellini, M. Domenica
    ANNALS OF HEMATOLOGY, 2013, 92 (11) : 1485 - 1493
  • [22] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Matt Shirley
    Greg L. Plosker
    Drugs, 2014, 74 : 1017 - 1027
  • [23] Prevalence and Associated Factors of Zinc and Vitamin D Deficiencies in Pediatric and Young Adult Patients with Non-Transfusion-Dependent Thalassemia
    Rodchaprom, Poonyapon
    Fanhchaksai, Kanda
    Maneekesorn, Supawadee
    Kittisakmontri, Kulnipa
    Charoenkwan, Pimlak
    HEMOGLOBIN, 2025, : 73 - 77
  • [24] Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
    Porter, John B.
    Cappellini, Maria Domenica
    Kattamis, Antonis
    Viprakasit, Vip
    Musallam, Khaled M.
    Zhu, Zewen
    Taher, Ali T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 288 - 299
  • [25] Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia
    Meloni, Antonella
    Pistoia, Laura
    Ricchi, Paolo
    Bagnato, Sergio
    Longo, Filomena
    Messina, Giuseppe
    Bagnato, Sabrina
    Rossi, Vincenza
    Renne, Stefania
    Righi, Riccardo
    Fina, Priscilla
    Positano, Vincenzo
    Cademartiri, Filippo
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1887 - 1896
  • [26] Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia
    Antonella Meloni
    Laura Pistoia
    Paolo Ricchi
    Sergio Bagnato
    Filomena Longo
    Giuseppe Messina
    Sabrina Bagnato
    Vincenza Rossi
    Stefania Renne
    Riccardo Righi
    Priscilla Fina
    Vincenzo Positano
    Filippo Cademartiri
    Annals of Hematology, 2024, 103 : 1887 - 1896
  • [27] Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors
    Teawtrakul, Nattiya
    Jetsrisuparb, Arunee
    Sirijerachai, Chittima
    Chansung, Kanchana
    Wanitpongpun, Chinadol
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 39 : 53 - 56
  • [28] Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia
    Luo, Yunchen
    Bajoria, Rekha
    Lai, Yongrong
    Pan, Hongfei
    Li, Qiaochuan
    Zhang, Zhongming
    Yang, Pijian
    Chatterjee, Ratna
    Liang, Yuzhen
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 457 - 468
  • [29] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Ali T. Taher
    John B. Porter
    Vip Viprakasit
    Antonis Kattamis
    Suporn Chuncharunee
    Pranee Sutcharitchan
    Noppadol Siritanaratkul
    Renzo Galanello
    Zeynep Karakas
    Tomasz Lawniczek
    Dany Habr
    Jacqueline Ros
    Zewen Zhu
    M. Domenica Cappellini
    Annals of Hematology, 2013, 92 : 1485 - 1493
  • [30] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
    Kontoghiorghe, Christina N.
    Kontoghiorghes, George J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 465 - 481